metformin has been researched along with Pituitary Neoplasms in 11 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Pituitary Neoplasms: Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Ten adolescents with hyperinsulinemia and dyslipidemia received therapy with metformin (500-1500 mg/daily) and micronized fenofibrate (160 mg/daily)." | 7.81 | Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience. ( Kalina, MA; Kalina-Faska, B; Mandera, M; Małecka Tendera, E; Skała-Zamorowska, E; Wilczek, M, 2015) |
| "Metformin is an anti-hyperglycemic agent used to treat diabetes, and recent evidence suggests it has antitumor efficacy." | 5.46 | Metformin inhibits proliferation and growth hormone secretion of GH3 pituitary adenoma cells. ( An, J; Duan, L; He, J; Hu, J; Li, S; Pei, X; Shen, R; Yang, H; Zang, Z; Zhang, W; Zhang, Y; Zheng, X; Zhou, Z; Zhu, F, 2017) |
| " Ten adolescents with hyperinsulinemia and dyslipidemia received therapy with metformin (500-1500 mg/daily) and micronized fenofibrate (160 mg/daily)." | 3.81 | Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience. ( Kalina, MA; Kalina-Faska, B; Mandera, M; Małecka Tendera, E; Skała-Zamorowska, E; Wilczek, M, 2015) |
| "Metformin was found to be effective in both cell types at the same concentrations, although the outcome of the treatment was quite the opposite." | 1.56 | Differential effects of metformin on reductive activity and energy production in pituitary tumor cells compared to myogenic precursors. ( Giustina, A; Missale, C; Paghera, S; Tulipano, G, 2020) |
| "Prolactinomas are the most common functional pituitary adenomas and dopamine agonists are the primary therapy." | 1.48 | Combination Treatment with Bromocriptine and Metformin in Patients with Bromocriptine-Resistant Prolactinomas: Pilot Study. ( Bao, X; Deng, K; Feng, M; Gao, J; Liu, X; Liu, Y; Wang, R; Yao, Y, 2018) |
| "Metformin is a commonly used antidiabetic drug that has been widely used to control the hyperglycemia that occurs in patients with CD, which is secondary to both cortisol excess and pasireotide treatment." | 1.48 | Metformin suppresses growth and adrenocorticotrophic hormone secretion in mouse pituitary corticotroph tumor AtT20 cells. ( Huang, H; Jin, K; Mu, J; Pu, J; Ruan, L; Tan, S; Wang, F; Yang, G; Zhong, A, 2018) |
| "Metformin is an anti-hyperglycemic agent used to treat diabetes, and recent evidence suggests it has antitumor efficacy." | 1.46 | Metformin inhibits proliferation and growth hormone secretion of GH3 pituitary adenoma cells. ( An, J; Duan, L; He, J; Hu, J; Li, S; Pei, X; Shen, R; Yang, H; Zang, Z; Zhang, W; Zhang, Y; Zheng, X; Zhou, Z; Zhu, F, 2017) |
| "Majority of acromegaly are due to pituitary adenoma." | 1.37 | Diagnosis and management of acromegaly: giant invasive adenoma. ( Cahyanur, R; Purnamasari, D; Setyawan, W; Setyowati, S; Soewondo, P; Sudrajat, DG, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Vázquez-Borrego, MC | 1 |
| Fuentes-Fayos, AC | 1 |
| Herrera-Martínez, AD | 1 |
| Venegas-Moreno, E | 1 |
| L-López, F | 1 |
| Fanciulli, A | 1 |
| Moreno-Moreno, P | 1 |
| Alhambra-Expósito, MR | 1 |
| Barrera-Martín, A | 1 |
| Dios, E | 1 |
| Blanco-Acevedo, C | 1 |
| Solivera, J | 1 |
| Granata, R | 1 |
| Kineman, RD | 1 |
| Gahete, MD | 1 |
| Soto-Moreno, A | 1 |
| Gálvez-Moreno, MA | 1 |
| Castaño, JP | 1 |
| Luque, RM | 1 |
| Tulipano, G | 2 |
| Paghera, S | 1 |
| Missale, C | 1 |
| Giustina, A | 2 |
| An, J | 1 |
| Pei, X | 1 |
| Zang, Z | 1 |
| Zhou, Z | 1 |
| Hu, J | 1 |
| Zheng, X | 1 |
| Zhang, Y | 1 |
| He, J | 1 |
| Duan, L | 1 |
| Shen, R | 1 |
| Zhang, W | 1 |
| Zhu, F | 1 |
| Li, S | 1 |
| Yang, H | 1 |
| Faggi, L | 1 |
| Liu, X | 1 |
| Liu, Y | 1 |
| Gao, J | 1 |
| Feng, M | 1 |
| Bao, X | 1 |
| Deng, K | 1 |
| Yao, Y | 1 |
| Wang, R | 1 |
| Jin, K | 1 |
| Ruan, L | 1 |
| Pu, J | 1 |
| Zhong, A | 1 |
| Wang, F | 1 |
| Tan, S | 1 |
| Huang, H | 1 |
| Mu, J | 1 |
| Yang, G | 1 |
| Kalina, MA | 1 |
| Wilczek, M | 1 |
| Kalina-Faska, B | 1 |
| Skała-Zamorowska, E | 1 |
| Mandera, M | 1 |
| Małecka Tendera, E | 1 |
| Krysiak, R | 1 |
| Szkróbka, W | 1 |
| Okopień, B | 1 |
| Cahyanur, R | 1 |
| Setyawan, W | 1 |
| Sudrajat, DG | 1 |
| Setyowati, S | 1 |
| Purnamasari, D | 1 |
| Soewondo, P | 1 |
| Ali, O | 1 |
| Banerjee, S | 1 |
| Kelly, DF | 1 |
| Lee, PD | 1 |
| Güven, A | 1 |
| Ozgen, T | 1 |
| Belet, U | 1 |
| Aydin, M | 1 |
11 other studies available for metformin and Pituitary Neoplasms
| Article | Year |
|---|---|
Statins Directly Regulate Pituitary Cell Function and Exert Antitumor Effects in Pituitary Tumors.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, A | 2020 |
Differential effects of metformin on reductive activity and energy production in pituitary tumor cells compared to myogenic precursors.
Topics: Animals; Cell Survival; Glucose; Metformin; Pituitary Gland; Pituitary Neoplasms; Rats | 2020 |
Metformin inhibits proliferation and growth hormone secretion of GH3 pituitary adenoma cells.
Topics: Activating Transcription Factor 3; Adenoma; Adult; Aged; Animals; Cell Line, Tumor; Cell Proliferati | 2017 |
Effects of metformin on cell growth and AMPK activity in pituitary adenoma cell cultures, focusing on the interaction with adenylyl cyclase activating signals.
Topics: Adenylate Kinase; Adenylyl Cyclases; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Anim | 2018 |
Combination Treatment with Bromocriptine and Metformin in Patients with Bromocriptine-Resistant Prolactinomas: Pilot Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bromocriptine; Female; Humans; Male; Metformi | 2018 |
Metformin suppresses growth and adrenocorticotrophic hormone secretion in mouse pituitary corticotroph tumor AtT20 cells.
Topics: Adenylate Kinase; Adrenocorticotropic Hormone; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Prolife | 2018 |
Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience.
Topics: Adolescent; Carbohydrates; Child; Child, Preschool; Craniopharyngioma; Dyslipidemias; Female; Fenofi | 2015 |
A Neutral Effect of Metformin Treatment on Macroprolactin Content in Women with Macroprolactinemia.
Topics: Adult; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hyperprolactinemia; Metformi | 2017 |
Diagnosis and management of acromegaly: giant invasive adenoma.
Topics: Acromegaly; Bromocriptine; Follicle Stimulating Hormone; Growth Hormone; Hormone Antagonists; Humans | 2011 |
Management of type 2 diabetes mellitus associated with pituitary gigantism.
Topics: Adenoma; Adolescent; Antineoplastic Agents; Cabergoline; Combined Modality Therapy; Diabetes Mellitu | 2007 |
Acromegaly symptoms without pituitary adenoma in an adolescent.
Topics: Acromegaly; Adolescent; Drug Therapy, Combination; Facies; Glucose Tolerance Test; Hormone Antagonis | 2007 |